Cyclothymia: Independent Evidence on Diagnosis, Treatment & Risk

Table of contents

• Evidence summary
• What cyclothymia is
• Symptoms, diagnosis and red flags
• Causes, risk factors and course
• Treatments: what works and what does not
• Medicines
• Supplements and lifestyle claims
• Risks of common treatments
• Who to see
• Follow the money: who funds the research and who profits
• Related research
• Frequently asked questions
• Sources and funding notes

Evidence summary

Independent evidence and credibility scorecard

Independence tiers: 1 = regulator, government or national guideline body; 2 = academic team with public, charitable or no declared commercial funding for the work; 3 = therapy developers testing their own therapy, or documents written or published by a drug company; 4 = manufacturer-funded or manufacturer-authored promotional evidence. Credibility runs from A (highest) to D.

Clustering: The clinical literature on cyclothymia is concentrated in a few groups in Italy (Pisa, Bologna, Sardinia), France and the US. The main treatment trial and much of the expert advice come from Italy, and the most cited reference work (MSD) relies on the Italian–French review. Where these sources agree, that is not fully independent confirmation. The strongest convergence is between the UK regulator, the US label and academic reviewers, who all warn about antidepressants used without a mood stabiliser in bipolar-prone people.

What cyclothymia is

Cyclothymia is a chronic mood condition. People have repeated low periods and repeated "up" periods, but neither reaches the threshold for a major depressive episode or for mania. The NHS calls it "a mild form of bipolar disorder" and notes that lows and highs are fairly frequent, with no more than about 2 months of normal mood at a time (NHS). "Mild" describes how intense each swing is, not how much the condition disrupts life. Reviewers describe cyclothymia as a prevalent and impairing disorder across the lifespan (Van Meter 2012, Clinical Psychology Review).

• Names and codes: cyclothymic disorder (DSM-5-TR); 6A62 in WHO's ICD-11 (ICD-11); F34.0 "cyclothymia" in ICD-10 (Baldessarini 2011).
• History: The idea goes back to Karl Kahlbaum and Ewald Hecker in the late 1800s. Classification has shifted between editions; we could not verify the exact DSM-III history (Baldessarini 2011).
• Temperament or disorder? Some researchers see cyclothymia mainly as an exaggerated "cyclothymic temperament" that starts early in life (Perugi 2017). An Australian review proposed placing the disorder within the bipolar II class (Parker 2012). This debate matters: broader definitions would label many more people.
• How common: Lifetime prevalence estimates vary; we could not verify the lower population figures often quoted. The MSD Manual gives up to 2.5% in the MSD Manual, which notes similar rates in women and men (MSD Manual). Specialist groups report much higher figures in clinics, for example 20–50% of people seeking help for mood, anxiety, impulse-control and addictive problems "after careful screening" using a broader definition than DSM-5 (Perugi 2015). Treat these clinic figures as one school's estimate, not population data.

Symptoms, diagnosis and red flags

Typical symptoms

• Up periods: more energy, less need for sleep, more talkative and sociable, more confident (NHS). Irritability is common. In US youth samples, irritability and impulsive aggression were higher than in non-bipolar conditions and linked to poorer friendships and social functioning (Van Meter 2016).
• Low periods: low mood, loss of interest and tiredness that do not reach the level of clinical depression (NHS).
• Effects on life: an uneven work or school history, frequent moves, repeated relationship break-ups and episodes of alcohol or drug misuse (MSD Manual). In an Italian clinic sample of 62 people with "pure" cyclothymia, more than half also met criteria for an anxiety disorder (Tomba 2012).

Formal criteria

DSM-5-TR requires, for at least 2 years (1 year in children and adolescents): numerous periods of hypomanic symptoms and of depressive symptoms that never meet full episode criteria; symptoms present at least half the time; no symptom-free gap longer than 2 months; and clinically significant distress or impairment not better explained by another condition, substance or medicine (MSD Manual, citing DSM-5-TR). ICD-11 uses a similar 2-year rule. It allows the "up" symptoms to sometimes meet hypomania criteria but excludes any history of manic or mixed episodes (ICD-11, 6A62). In a study of 1,357 clinicians in the WHO Global Clinical Practice Network using case vignettes, diagnostic accuracy for cyclothymic disorder was similar under ICD-11 and ICD-10 (Kogan 2021).

How it is assessed, and what it can be confused with

There is no blood test or scan. Diagnosis rests on a careful history, ideally with mood charting over time and input from someone who knows the person well. NICE's guideline, written for bipolar type I and II, asks GPs to ask anyone with depression about past periods of overactivity or disinhibited behaviour. If these lasted 4 days or more, it suggests considering referral (NICE CG185, 1.2.1). It advises against using questionnaires in primary care to identify bipolar disorder (1.2.3). NICE's full guideline adds that diagnoses are generally more reliable for bipolar type I than for bipolar II or cyclothymia, and that telling bipolar II apart from cyclothymia depends on careful attention to history and episode length (NICE full guideline).

Conditions that overlap include bipolar II disorder, borderline personality disorder, ADHD, anxiety disorders and substance misuse. Reviewers note that cyclothymia is "rarely diagnosed" despite evidence that it may be the most common form of bipolar disorder (Van Meter 2012). In a US clinic sample of 827 young people, cyclothymia could be told apart from non-mood disorders by irritability, sleep disturbance, age at onset, other diagnoses and family history (Van Meter 2011). Thyroid problems, other medical conditions and substances also need to be ruled out (MSD Manual).

Causes, risk factors and course

• Family history: First-degree relatives of people with cyclothymia have more bipolar disorder and major depression than expected, and cyclothymia is more common in relatives of people with bipolar disorder (Baldessarini 2011). The NHS says the cause is unknown but likely partly genetic, and that trauma or long-term stress may act as triggers (NHS).
• Early onset: In one US youth sample described in a review, three-quarters had symptoms before age 10, with an average age at onset of 6 (Van Meter 2012).
• Progression to bipolar type I or II: Studies of young adults and adults suggest about a third of cases progress to bipolar type I or II. In one longitudinal study of adolescents, about half progressed to bipolar II during follow-up (Van Meter 2012). In a French follow-up of depressed children and teenagers, a substantial share were diagnosed with bipolar disorder, more often those with cyclothymic temperament at the start (exact figures not verified; Kochman 2005).
• Not everyone gets worse: Some people manage cyclothymia as a lifelong condition without progressing (NHS), and reviewers describe trajectories "from remission to escalation" (Van Meter 2012).
• Link with rapid cycling: At a Sardinian mood clinic, lifetime rapid cycling was 4.5 times more common in patients with a cyclothymic temperament (16.8% vs 3.7%). These were unpublished data quoted by the clinic's own researchers (Baldessarini 2011).

Treatments: what works and what does not

Psychological therapy: the one positive trial

The only randomised trial of psychotherapy in adult cyclothymic disorder enrolled 62 untreated patients in Bologna. Half received CBT (6 sessions) followed by well-being therapy (4 sessions). The other half received clinical management, a supportive and advisory approach with the same number of 45-minute sessions every 2 weeks. (Baldessarini 2011; Fava 2011). An independent assessor, blind to the group, rated outcomes.

We do not chart the symptom percentages. The exact figures from the trial could not be verified from the abstract we accessed.

In plain English: the abstract reports that both groups improved, that the therapy group improved more, and that gains were held for 2 years. There are important limits. We could not verify baseline balance or the share of participants with bipolar II from the sources we accessed. People with substance misuse or personality disorders were excluded, so the results may not apply to more complex cases (Baldessarini 2011). The authors developed well-being therapy, and the trial has not been repeated by an independent team.

Beyond this trial, the evidence is very thin. Two published single-patient CBT studies in cyclothymia, each with mood rated every 4 hours for close to a year, showed less day-to-day mood variability after therapy (Totterdell 2008; Totterdell 2012). A review found no psychotherapy studies at all in young people with cyclothymia (Van Meter 2012). For people with diagnosed bipolar disorder, NICE recommends a bipolar-specific manualised psychological intervention or CBT, interpersonal therapy or behavioural couples therapy for bipolar depression (NICE CG185, 1.6.1). For cyclothymia, this is borrowed advice.

What is being tested now

UK researchers funded by the NIHR are running STABILISE, a feasibility trial of an adapted behavioural therapy for ongoing low mood or mood instability between episodes in bipolar spectrum disorders. Its protocol explicitly mentions cyclothymic disorder and aims to recruit 60 people (STABILISE protocol, 2025). Its predecessor, ThrIVe-B, recruited 43 people, all with bipolar type I or II. It showed the design was broadly feasible, but only 50% of the therapy group attended at least half the sessions (ThrIVe-B, 2021). Our ClinicalTrials.gov search for "cyclothymic" in October 2026 found no registered drug trial focused on adult cyclothymic disorder (ClinicalTrials.gov).

Medicines

No UK medicine label we checked lists cyclothymia as an indication. Lamictal (lamotrigine) is licensed in bipolar type I disorder to prevent depressive episodes (Lamictal SmPC). Priadel (lithium) covers acute mania and hypomania, prophylaxis of bipolar disorder, recurrent depression that has not responded to other antidepressants, and aggressive or self-harming behaviour (Priadel SmPC). Seroquel (quetiapine) is licensed for manic and depressive episodes in bipolar disorder (Seroquel SmPC). The Epilim valproate tablets we checked are licensed for epilepsy only (Epilim SmPC). Any use of these medicines in cyclothymia is therefore off-label, guided by specialist judgement. The NHS lists lithium, carbamazepine, oxcarbazepine, sodium valproate and some antipsychotics such as quetiapine as options (NHS).

Lithium

A US clinic followed 69 people with cyclothymia, 102 with bipolar II and 43 with unipolar depression on lithium. After 2 years, only 26–36% of the cyclothymic group were estimated to have stayed free of a depressive episode, the lowest of the three groups (Peselow 1982). With no untreated comparison group, this cannot show whether lithium helped. Specialist reviewers describe a "mild to moderate" effect of lithium and some anticonvulsants, based mainly on naturalistic reports and expert opinion (Perugi 2017). For lithium's benefits and kidney, thyroid and toxicity risks in bipolar disorder, see our lithium review.

Valproate

In an open series, 15 people with cyclothymia and 11 with bipolar II took low-dose valproate (125–500 mg a day). In total, 26 of 33 rapid-cycling patients reported partial or complete stabilisation. People with cyclothymia needed lower doses than those with bipolar II (Jacobsen 1993). There was no control group or blinding. Valproate now carries strict UK restrictions (see Risks below).

Lamotrigine

An open, uncontrolled study treated 24 women with cyclothymic temperament and treatment-resistant depression with lamotrigine. Most were also taking an antidepressant, and 75% met criteria for bipolar II. Of 23 who stayed in the study, 16 (70%) had a sustained response (Manning 2005). This was not a cyclothymic disorder sample, and there was no control group. Baldessarini's group describes evidence for lamotrigine in this area as "limited and inconsistent" (Baldessarini 2011).

Antipsychotics

A four-patient case report described remission with low-dose quetiapine (25–75 mg at night) in people with cyclothymic or hyperthymic temperament (Bisol 2010). The only placebo-controlled drug trial we found that included cyclothymic disorder tested aripiprazole in 59 children and teenagers with cyclothymia or BP-NOS who had a parent with bipolar disorder. Aripiprazole reduced mania scores more than placebo over 12 weeks, but caused more weight gain (2.3 kg vs 0.7 kg) (Findling 2017). It does not show long-term benefit or prevention of bipolar disorder.

Antidepressants

Many people with cyclothymia seek help during low periods and are given antidepressants. Baldessarini's group says the value of antidepressants is "not sufficiently well studied" to judge either their benefit or their risk of destabilising mood (Baldessarini 2011). The Italian–French specialists who favour a broad cyclothymia diagnosis go further. They report high rates of antidepressant-induced hypomanic and mixed switches in their patients, and advise gradually withdrawing unnecessary antidepressants (Perugi 2017). The MSD Manual reserves antidepressants for severe, prolonged depression with close monitoring (MSD Manual). These sources agree on caution, but they disagree on how big the risk is.

Supplements and lifestyle claims

Risks of common treatments

Psychological therapy has few physical risks. In the UK ThrIVe-B trial, five serious adverse events occurred. None were unexpected, and one "may possibly" have been linked to study procedures (ThrIVe-B). The less visible risk is under-treatment: a mood-swing pattern labelled as personality or "just stress" may delay assessment for bipolar disorder. Reviewers link this delay to worse outcomes (Van Meter 2011).

Who to see

• Start with a GP or family doctor. The NHS advises seeing a GP if you think you may have cyclothymia (NHS). Bring a few weeks of mood and sleep notes, and any family history of bipolar disorder, depression or suicide.
• Specialist assessment: NICE says suspected bipolar disorder should be assessed in a service offering the full range of medical and psychological treatments, such as a specialist bipolar or community mental health team (NICE CG185, 1.3.1). A psychiatrist is usually needed to start lithium or valproate. NICE advises against starting either in primary care for bipolar disorder, except lithium under shared care (1.2.7–1.2.8).
• Psychological therapy: A clinical psychologist or CBT therapist with experience of bipolar spectrum conditions. NICE asks that therapists working with bipolar depression have bipolar-specific training (NICE CG185, 1.6.2).
• Pharmacist: For checking interactions, especially with lithium, and before adding any supplement.
• Children and teenagers: CAMHS or a child psychiatrist. Irritability and aggression in young people are common in many conditions and do not on their own mean cyclothymia (Van Meter 2016).

Follow the money: who funds the research and who profits

Who profits from treatment

• No dedicated product: We found no UK medicine licensed specifically for cyclothymia. The medicines used are mostly older and available as generics. Brand holders listed on UK labels include The Wellcome Foundation, trading as GlaxoSmithKline UK, for Lamictal (emc), Sanofi for Epilim (emc), Luye Pharma for Seroquel (emc) and Essential Pharma (Malta) for Priadel lithium (emc). The US Zoloft label is held by Viatris (DailyMed).
• The commercial interest is indirect. Wider "bipolar spectrum" definitions would make more people eligible for mood stabilisers and antipsychotics already licensed for bipolar type I. We found no evidence that any company funded the cyclothymia research cited here. Some authors in the wider field declared industry links, for example a co-author of the main youth reviews declared Bristol-Myers Squibb travel support and Lundbeck consulting (Van Meter 2012).
• Therapy and reputational interests: The positive therapy trial was run by the group that developed well-being therapy (Fava 2011). Its lead author edited the publishing journal for 30 years, stepping down in 2022 (Karger). This is a documented academic interest, not evidence that the result is wrong. Specialist authors who argue for broader diagnostic rules also cite their own books on the subject (Perugi 2017, reference list).

Who funded the evidence

• US federal research: NIMH grants are reported for the US youth validity and long-term cohort studies (Van Meter 2011; Van Meter 2017), the routine-regularity cohort (Shen 2008), the omega-3 analysis (Vesco 2018) and the family-focused therapy trial (Miklowitz 2020).
• UK public research: NIHR funded ThrIVe-B (2021) and STABILISE. A STABILISE author declared directorship of and shares in CareLoop Health, a University of Manchester digital mental-health start-up, and the lead author declared occasional paid workshops on bipolar therapies for academic and health organisations, plus consultancy for CareLoop (STABILISE protocol).
• Charitable funding: The Baldessarini commentary was supported by the Bruce J. Anderson Foundation and a McLean Hospital private donors fund. Its authors declared no financial involvement with drug companies (Baldessarini 2011).
• Unknown: We could not find funding statements for the Fava trial abstract, the Findling aripiprazole trial, the Peselow, Jacobsen and Manning case series, or the Tondo 2024 switching study.

Guideline panels

NICE CG185 was developed by the National Collaborating Centre for Mental Health, funded by NICE and led by the Royal College of Psychiatrists and the British Psychological Society (NICE full guideline). Panel members' declarations are published. The chair declared £1,000 from Lundbeck in 2012 for a talk on clinical pathways that did not review any medication. The panel's chief pharmacist declared one Sunovion advisory board on lurasidone for schizophrenia and did not take part in discussions about that drug (NICE CG185 appendix 2). These declarations concern bipolar type I and II. No guideline panel we found has issued cyclothymia-specific treatment advice.

Integrity events

We found no regulatory action, recall or lawsuit specific to cyclothymia treatment. The main documented regulatory event affecting treatment choice is the UK's tightening of valproate rules for people under 55 (MHRA).

Related research

For wider, evidence-graded context, see these Pure City Research guides:

• Bipolar depression: assessment, treatment evidence and safety
• Lithium: independent evidence on bipolar, suicide and kidney risk
• Persistent depressive disorder
• Major depressive disorder
• Cognitive behavioural therapy (CBT)
• Antidepressant withdrawal and dependence
• Premenstrual dysphoric disorder (PMDD)
• Mindfulness-based therapy
• Omega-3: which form actually works
• Supplements for stress, anxiety and depression

Frequently asked questions

Sources and funding notes

What we could not verify: We could not access the full text or funding statement of the Fava 2011 trial (we relied on its abstract and an accompanying commentary), the Findling 2017 aripiprazole trial, or the Peselow, Jacobsen and Manning case series. The Tomba 2016 pilot on demoralisation in the Fava sample had no abstract, so we did not use it. We could not open the NIH StatPearls chapter or the DSM-5-TR text directly, so DSM criteria are taken from the MSD Manual's summary. The ICD-11 wording was checked through the WHO browser entry and a search summary of it, not a downloaded copy. Several figures could not be verified and were removed or rephrased: the Fava 2011 percentage changes, the Tondo 2024 switching rate, the Kochman 2005 counts, the Manning 2005 and Jacobsen 1993 counts, the DSM-III history, the 0.4–1.0% prevalence range, and the Shen 2008 trial description. Population prevalence figures come from secondary summaries rather than the original surveys, and we found no UK population estimate. We did not trace WHO's own funding for this article, the omega-3 capsule supplier in the OATS trials, or current ownership of the brand holders beyond UK label listings.

1. NICE CG185: Bipolar disorder: assessment and management (published 2014, last updated September 2025): UK guideline; NICE.
2. NICE CG185 full guideline (NCCMH): scope wording on cyclothymia not confirmed; NCCMH funded by NICE.
3. NICE CG185 appendices 1–10 (declarations of interest): NICE.
4. NHS: Cyclothymia (reviewed 9 October 2023): UK DHSC.
5. MHRA: new measures to reduce serious harms of valproate: UK regulator.
6. MHRA: update on 2-specialist review requirements for male patients already taking valproate (13 February 2025): UK regulator.
7. WHO ICD-11 for Mortality and Morbidity Statistics, 6A62 Cyclothymic disorder: WHO.
8. Kogan CS et al. ICD-11 mood disorders global field study. J Affect Disord 2021: funding not verified.
9. MSD Manual Professional: Cyclothymic disorder: clinical reference; Merck & Co., Inc.
10. Baldessarini RJ, Vázquez G, Tondo L. Treatment of cyclothymic disorder: commentary. Psychother Psychosom 2011 (PDF): Bruce J. Anderson Foundation; McLean Private Donors fund; no pharma ties.
11. Fava GA et al. Sequential CBT and well-being therapy in cyclothymic disorder. Psychother Psychosom 2011: RCT; University of Bologna; funding not stated in abstract.
12. Karger: Farewell to Prof Giovanni A Fava after 30 years: journal editorial history.
13. Van Meter AR, Youngstrom EA, Findling RL. Cyclothymic disorder: a critical review. Clin Psychol Rev 2012: academic review; no funding listed on PubMed.
14. Van Meter AR et al. Cyclothymic disorder in youth. Neuropsychiatry (London) 2012: review; co-author declared NIH/Ohio grants, BMS travel, Lundbeck consulting.
15. Van Meter A et al. Examining the validity of cyclothymic disorder in a youth sample. J Affect Disord 2011: NIMH R01 MH066647.
16. Van Meter AR et al. Longitudinal course of cyclothymic disorder in youth (LAMS). J Affect Disord 2017: NIMH grants.
17. Van Meter A et al. Irritability and impulsive aggression in youth with cyclothymic disorder. J Child Adolesc Psychopharmacol 2016: no funding listed on PubMed.
18. Perugi G, Hantouche E, Vannucchi G. Diagnosis and treatment of cyclothymia. Curr Neuropharmacol 2017: expert review; no funding or conflicts declared.
19. Perugi G et al. Cyclothymia reloaded. J Affect Disord 2015: expert review; funding not listed on PubMed.
20. Parker G et al. Cyclothymia. Depress Anxiety 2012: conceptual review.
21. Tomba E et al. Clinical configuration of cyclothymic disturbances. J Affect Disord 2012: Italian case-control study.
22. Kochman FJ et al. Cyclothymic temperament as a prospective predictor of bipolarity and suicidality in children and adolescents. J Affect Disord 2005: French cohort; funding not verified.
23. Tondo L et al. Antidepressant-associated diagnostic change from MDD to bipolar disorder. Acta Psychiatr Scand 2024: the paper exists, but its figures could not be checked; not relied on.
24. Peselow ED et al. Lithium prophylaxis of depression in unipolar, bipolar II and cyclothymic patients. Am J Psychiatry 1982: uncontrolled cohort; no funding statement found.
25. Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J Clin Psychiatry 1993: open series; funding not verified.
26. Manning JS et al. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives. J Affect Disord 2005: open study; funding not verified.
27. Bisol LW, Lara DR. Low-dose quetiapine for patients with dysregulation of hyperthymic and cyclothymic temperaments. J Psychopharmacol 2010: four-case report.
28. Findling RL et al. Aripiprazole in symptomatic youths at genetic high risk for bipolar disorder. J Child Adolesc Psychopharmacol 2017: RCT; funding not verified.
29. Miklowitz DJ et al. Family-focused therapy for youths at high risk for bipolar disorder. JAMA Psychiatry 2020: RCT; NIMH grants.
30. Wright K et al. ThrIVe-B feasibility RCT. Int J Bipolar Disord 2021: NIHR RfPB PB-PG-1215-20023; no competing interests.
31. STABILISE feasibility trial protocol. Pilot Feasibility Stud 2025: NIHR302220; declared CareLoop Health interests.
32. Totterdell P et al. Restructuring mood in cyclothymia using CBT. J Clin Psychol 2008: single-case study.
33. Totterdell P et al. CBT for cyclothymia: cognitive regulatory control. Behav Cogn Psychother 2012: single-case study.
34. Shen GH et al. Lifestyle regularity and cyclothymic symptomatology. J Clin Psychol 2008: observational cohort; funding not verified.
35. Vesco AT et al. Omega-3 and executive function in youth with mood disorders (OATS). J Child Psychol Psychiatry 2018: NIMH/NIH grants.
36. Zoloft (sertraline) US prescribing information, DailyMed (revised 8/2023): FDA-approved label; Viatris.
37. Lamictal tablets SmPC, Epilim 200 mg SmPC, Seroquel 100 mg SmPC, Priadel 400 mg SmPC: UK labels; marketing-authorisation holders.
38. NHS: side effects of lamotrigine and NHS: side effects of quetiapine: UK DHSC.
39. ClinicalTrials.gov search: cyclothymic: US National Library of Medicine registry.

Educational research reviewed 6 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.